Generic Depakene Availability

Depakene is a brand name of valproic acid, approved by the FDA in the following formulation(s):

DEPAKENE (valproic acid - capsule; oral)

  • Manufacturer: ABBVIE
    Approved Prior to Jan 1, 1982
    Strength(s): 250MG [RLD] [AB]

DEPAKENE (valproic acid - syrup; oral)

  • Manufacturer: ABBVIE
    Approved Prior to Jan 1, 1982
    Strength(s): 250MG/5ML [RLD] [AA]

Has a generic version of Depakene been approved?

Yes. The following products are equivalent to Depakene:

valproic acid capsule; oral

  • Manufacturer: BANNER PHARMACAPS
    Approval date: June 29, 1993
    Strength(s): 250MG [AB]
  • Manufacturer: CATALENT
    Approval date: October 29, 1991
    Strength(s): 250MG [AB]
  • Manufacturer: SUN PHARM INDS LTD
    Approval date: February 22, 2013
    Strength(s): 250MG [AB]

valproic acid syrup; oral

  • Manufacturer: ALPHARMA
    Approval date: December 22, 2000
    Strength(s): 250MG/5ML [AA]
  • Manufacturer: HIGH TECH PHARMA
    Approval date: January 13, 1995
    Strength(s): 250MG/5ML [AA]
  • Manufacturer: PHARM ASSOC
    Approval date: December 15, 2000
    Strength(s): 250MG/5ML [AA]
  • Manufacturer: SUN PHARM INDS INC
    Approval date: May 28, 2010
    Strength(s): 250MG/5ML [AA]
  • Manufacturer: TEVA PHARMS
    Approval date: August 25, 1992
    Strength(s): 250MG/5ML [AA]
  • Manufacturer: VINTAGE
    Approval date: October 13, 2006
    Strength(s): 250MG/5ML [AA]
  • Manufacturer: WOCKHARDT
    Approval date: July 1, 1986
    Strength(s): 250MG/5ML [AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Depakene. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Depakene.

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AAProducts in conventional dosage forms not presenting bioequivalence problems. Products coded as AA contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate in vitro bioequivalence standard that is acceptable to the Agency in order to be approved.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Advertisement
Close

Recommended

(web3)